Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics
Jelena Grahovac, Tatjana Srdić-Rajić, Juan Francisco Santibañez, Marijana Pavlović, Milena Čavić, Siniša Radulović, Jelena Grahovac, Tatjana Srdić-Rajić, Juan Francisco Santibañez, Marijana Pavlović, Milena Čavić, Siniša Radulović
Abstract
Objective: Despite recent advancements in targeted therapy and immunotherapies, prognosis for metastatic melanoma patients remains extremely poor. Development of resistance to previously effective treatments presents a serious challenge and new approaches for melanoma treatment are urgently needed. The objective of this study was to examine the effects of telmisartan, an AGTR1 inhibitor and a partial agonist of PPARγ, on melanoma cells as a potential agent for repurposing in melanoma treatment.
Methods: Expression of AGTR1 and PPARγ mRNA in melanoma patient tumor samples was examined in publicly available datasets and confirmed in melanoma cell lines by qRT-PCR. A panel of melanoma cell lines was tested in viability, apoptosis and metabolic assays in presence of telmisartan by flow cytometry and immunocytochemistry. A cytotoxic effect of combinations of telmisartan and targeted therapy vemurafenib was examined using the Chou-Talalay combination index method.
Results: Both AGTR1 and PPARγ mRNA were expressed in melanoma patient tumor samples and decreased compared to the expression in the healthy skin. In vitro, we found that telmisartan decreased melanoma cell viability by inducing cell apoptosis. Increased glucose uptake, but not utilization, in the presence of telmisartan caused the fission of mitochondria and release of reactive oxygen species. Telmisartan altered the cell bioenergetics, thereby synergizing with vemurafenib in vitro, and even sensitized vemurafenib-resistant cells to the treatment.
Conclusions: Given that the effective doses of telmisartan examined in our study can be administered to patients and that telmisartan is a widely used and safe antihypertensive drug, our findings provide the scientific rationale for testing its efficacy in treatment of melanoma progression.
Keywords: Melanoma; apoptosis; mitochondria; reactive oxygen species; targeted therapy; telmisartan.
Figures
References
- Luke JJ, Flaherty KT, Ribas A, Long GV Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14:463–82. doi: 10.1038/nrclinonc.2017.43.
- Seidel JA, Otsuka A, Kabashima K Anti-PD-1 and anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86. doi: 10.3389/fonc.2018.00086.
- Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu JX, Naraev N, et al Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. Onco Targets Ther. 2018;11:7095–107. doi: 10.2147/OTT.
- Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, et al Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis . Cancer Discov. 2014;4:423–33. doi: 10.1158/-13-0440.
- Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, et al Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF . Cancer Cell. 2013;23:302–15. doi: 10.1016/j.ccr.2013.02.003.
- Abildgaard C, Guldberg P Molecular drivers of cellular metabolic reprogramming in melanoma. Trends Mol Med. 2015;21:164–71. doi: 10.1016/j.molmed.2014.12.007.
- Shim JS, Liu JO Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Biol Sci. 2014;10:654–63. doi: 10.7150/ijbs.9224.
- Otake AH, Mattar AL, Freitas HC, Machado CML, Nonogaki S, Fujihara CK, et al Inhibition of angiotensin II receptor 1 limits tumor-associated angiogenesis and attenuates growth of murine melanoma. Cancer Chemother Pharmacol. 2010;66:79–87. doi: 10.1007/s00280-009-1136-0.
- Kliewer SA, Xu HE, Lambert MH, Willson TM Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res. 2001;56:239–63. doi: 10.1210/rp.56.1.239.
- Mössner R, Schulz U, Krüger U, Neumann C, Reich K, Middel P, et al Agonists of peroxisome proliferator-activated receptor γ inhibit cell growth in malignant melanoma. J Invest Dermatol. 2002;119:576–82. doi: 10.1046/j.1523-1747.2002.01861.x.
- Paulitschke V, Gruber S, Hofstätter E, Haudek-Prinz V, Klepeisz P, Schicher N, et al Proteome analysis identified the PPARγ ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction. PLoS One. 2012;7:e46103. doi: 10.1371/journal.pone.0046103.
- Botton T, Puissant A, Bahadoran P, Annicotte JS, Fajas L, Ortonne JP, et al In vitro and in vivo anti-melanoma effects of ciglitazone . J Invest Dermatol. 2009;129:1208–18. doi: 10.1038/jid.2008.346.
- Zhang SL, Wang YY Telmisartan inhibits NSCLC A549 cell proliferation and migration by regulating the PI3K/AKT signaling pathway. Oncol Lett. 2018;15:5859–64.
- Rasheduzzaman M, Moon JH, Lee JH, Nazim UM, Park SY Telmisartan generates ROS-dependent upregulation of death receptor 5 to sensitize TRAIL in lung cancer via inhibition of autophagy flux . Int J Biochem Cell Biol. 2018;102:20–30. doi: 10.1016/j.biocel.2018.06.006.
- Pu ZC, Zhu M, Kong DF Telmisartan prevents proliferation and promotes apoptosis of human ovarian cancer cells through upregulating PPARγ and downregulating MMP-9 expression. Mol Med Rep. 2016;13:555–9. doi: 10.3892/mmr.2015.4512.
- Oura K, Tadokoro T, Fujihara S, Morishita A, Chiyo T, Samukawa E, et al Telmisartan inhibits hepatocellular carcinoma cell proliferation in vitro by inducing cell cycle arrest. Oncol Rep. 2017;38:2825–35. doi: 10.3892/or.2017.5977.
- Fujihara S, Morishita A, Ogawa K, Tadokoro T, Chiyo T, Kato K, et al The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKα/mTOR pathway in vitro and in vivo . Oncotarget. 2017;8:8536–49.
- Fodstad O, Kjønniksen I, Aamdal S, Nesland JM, Boyd MR, Pihl A Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. Cancer Res. 1988;48:4382–8.
- Timenetsky J, Santos LM, Buzinhani M, Mettifogo E Detection of multiple mycoplasma infection in cell cultures by PCR. Braz J Med Biol Res. 2006;39:907–14. doi: 10.1590/S0100-879X2006000700009.
- Zou CH, Wang YJ, Shen ZF 2-NBDG as a fluorescent indicator for direct glucose uptake measurement. J Biochem Biophys Methods. 2005;64:207–15. doi: 10.1016/j.jbbm.2005.08.001.
- Chou TC, Talalay P Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27–55. doi: 10.1016/0065-2571(84)90007-4.
- Talantov D, Mazumder A, Yu JX, Briggs T, Jiang YQ, Backus J, et al Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res. 2005;11:7234–42. doi: 10.1158/1078-0432.CCR-05-0683.
- Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M, Wu M, et al Integrative genome comparison of primary and metastatic melanomas. PLoS One. 2010;5:e10770. doi: 10.1371/journal.pone.0010770.
- Riker AI, Enkemann SA, Fodstad O, Liu SH, Ren SP, Morris C, et al The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics. 2008;1:13. doi: 10.1186/1755-8794-1-13.
- Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP, et al Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res. 2008;6:760–9. doi: 10.1158/1541-7786.MCR-07-0344.
- Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, et al Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci USA. 2009;106:20429–34. doi: 10.1073/pnas.0905139106.
- Cheng XL, Holenya P, Can SZ, Alborzinia H, Rubbiani R, Ott I, et al A TrxR inhibiting gold(I) NHC complex induces apoptosis through ASK1-p38-MAPK signaling in pancreatic cancer cells. Mol Cancer. 2014;13:221.
- Cash TP, Pan Y, Simon MC Reactive oxygen species and cellular oxygen sensing. Free Radic Biol Med. 2007;43:1219–25. doi: 10.1016/j.freeradbiomed.2007.07.001.
- Suski JM, Lebiedzinska M, Bonora M, Pinton P, Duszynski J, Wieckowski MR Relation between mitochondrial membrane potential and ROS formation. Methods Mol Biol. 2012;810:183–205. doi: 10.1007/978-1-61779-382-0.
- Liemburg-Apers DC, Willems PHGM, Koopman WJH, Grefte S Interactions between mitochondrial reactive oxygen species and cellular glucose metabolism. Arch Toxicol. 2015;89:1209–26. doi: 10.1007/s00204-015-1520-y.
- Kim HI, Ahn YH Role of peroxisome proliferator-activated receptor-γ in the glucose-sensing apparatus of liver and β-cells. Diabetes. 2004;53 Suppl 1:S60–5.
- El-Kebbi IM, Roser S, Pollet RJ Regulation of glucose transport by pioglitazone in cultured muscle cells. Metabolism. 1994;43:953–8. doi: 10.1016/0026-0495(94)90173-2.
- Gottfried E, Rogenhofer S, Waibel H, Kunz-Schughart LA, Reichle A, Wehrstein M, et al Pioglitazone modulates tumor cell metabolism and proliferation in multicellular tumor spheroids. Cancer Chemother Pharmacol. 2011;67:117–26. doi: 10.1007/s00280-010-1294-0.
- Yu TZ, Robotham JL, Yoon Y Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci USA. 2006;103:2653–8. doi: 10.1073/pnas.0511154103.
- Yu TZ, Jhun BS, Yoon Y High-glucose stimulation increases reactive oxygen species production through the calcium and mitogen-activated protein kinase-mediated activation of mitochondrial fission. Antioxid Redox Signal. 2011;14:425–37. doi: 10.1089/ars.2010.3284.
- Haferkamp S, Borst A, Adam C, Becker TM, Motschenbacher S, Windhövel S, et al Vemurafenib induces senescence features in melanoma cells. J Invest Dermatol. 2013;133:1601–9. doi: 10.1038/jid.2013.6.
- Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, et al Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. J Clin Invest. 2016;126:1834–56. doi: 10.1172/JCI82661.
- Strohecker AM, White E Targeting mitochondrial metabolism by inhibiting autophagy in BRAF-driven cancers . Cancer Discov. 2014;4:766–72. doi: 10.1158/-14-0196.
- Corazao-Rozas P, Guerreschi P, André F, Gabert PE, Lancel S, Dekiouk S, et al Mitochondrial oxidative phosphorylation controls cancer cell's life and death decisions upon exposure to MAPK inhibitors. Oncotarget. 2016;7:39473–85.
- Chou TC Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440–6. doi: 10.1158/0008-5472.CAN-09-1947.
- Serasinghe MN, Wieder SY, Renault TT, Elkholi R, Asciolla JJ, Yao JL, et al Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors. Mol Cell. 2015;57:521–36. doi: 10.1016/j.molcel.2015.01.003.
- Anderson GR, Wardell SE, Cakir M, Yip C, Ahn YR, Ali M, et al Dysregulation of mitochondrial dynamics proteins are a targetable feature of human tumors. Nat Commun. 2018;9:1677. doi: 10.1038/s41467-018-04033-x.
- Pasquali S, Kefford R, Sileni VC, Nitti D, Rossi CR, Pilati P, et al Systemic treatments for metastatic cutaneous melanoma. Cochrane Database Syst Rev. 2018;2:CD011123..
- Nadanaciva S, Dykens JA, Bernal A, Capaldi RA, Will Y Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration . Toxicol Appl Pharmacol. 2007;223:277–87. doi: 10.1016/j.taap.2007.06.003.
- Scatena R, Bottoni P, Giardina B Mitochondria, PPARs, and cancer: is receptor-independent action of PPAR agonists a key? PPAR Res. 2008;2008:256251.
- Lakhter AJ, Hamilton J, Konger RL, Brustovetsky N, Broxmeyer HE, Naidu SR Glucose-independent acetate metabolism promotes melanoma cell survival and tumor growth. J Biol Chem. 2016;291:21869–79. doi: 10.1074/jbc.M115.712166.
- Hambright HG, Meng P, Kumar AP, Ghosh R Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells. Oncotarget. 2015;6:7195–208.
- Nogueira V, Hay N Molecular pathways: reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. Clin Cancer Res. 2013;19:4309–14. doi: 10.1158/1078-0432.CCR-12-1424.
- Smith AG, Beaumont KA, Smit DJ, Thurber AE, Cook AL, Boyle GM, et al PPARγ agonists attenuate proliferation and modulate Wnt/β-catenin signalling in melanoma cells. Int J Biochem Cell Biol. 2009;41:844–52. doi: 10.1016/j.biocel.2008.08.037.
- Veliceasa D, Schulze-Hoëpfner FT, Volpert OV PPARgamma and agonists against cancer: rational design of complementation treatments. PPAR Res. 2008;2008:945275.
- Tagami T, Yamamoto H, Moriyama K, Sawai K, Usui T, Shimatsu A, et al A selective peroxisome proliferator-activated receptor-γ modulator, telmisartan, binds to the receptor in a different fashion from thiazolidinediones. Endocrinology. 2009;150:862–70. doi: 10.1210/en.2008-0502.
- Schupp M, Clemenz M, Gineste R, Witt H, Janke J, Helleboid S, et al Molecular characterization of new selective peroxisome proliferator-activated receptor γ modulators with angiotensin receptor blocking activity. Diabetes. 2005;54:3442–52. doi: 10.2337/diabetes.54.12.3442.
- Stangier JC, Su CAPF, Roth W Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res. 2000;28:149–67. doi: 10.1177/147323000002800401.
- Cabaleiro T, Román M, Ochoa D, Talegón M, Prieto-Pérez R, Wojnicz A, et al Evaluation of the relationship between sex, polymorphisms in CYP2C8 and CYP2C9, and pharmacokinetics of angiotensin receptor blockers . Drug Metab Dispos. 2013;41:224–9. doi: 10.1124/dmd.112.046292.
Source: PubMed